8 terminated, 1 completed, 1 no longer available. 9 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Terminated 8, Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow IGM Biosciences, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies Imvotamab - Idiopathic Inflammatory Myopathies, Inflammatory Myopathies | Phase 1 | Terminated | IGM Biosciences, Inc. | 2 | 2024-05-29 | 2025-02-11 |
| Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma IGM-2644 - Multiple Myeloma | Phase 1 | Terminated | IGM Biosciences, Inc. | 4 | 2023-08-29 | 2024-08-01 |
| A Study of Imvotamab in Severe Systemic Lupus Erythematosus Imvotamab - Systemic Lupus Erythematosus, Lupus Erythematosus | Phase 1 | Terminated | IGM Biosciences, Inc. | 17 | 2023-08-15 | 2025-02-10 |
| A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis Imvotamab, Placebo - Rheumatoid Arthritis, Arthritis, Rheumatoid | Phase 1 | Terminated | IGM Biosciences, Inc. | 33 | 2023-03-15 | 2025-02-18 |
| Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer IGM-7354 - Solid Tumor | Phase 1 | Completed | IGM Biosciences, Inc. | 14 | 2023-01-10 | 2024-07-24 |
| Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19 IGM-6268, Placebo - Healthy Volunteers, COVID-19 | Phase 1 | Terminated | IGM Biosciences, Inc. | 26 | 2022-01-20 | 2022-10-14 |
| Evaluation of IGM-6268 in Healthy Volunteers IGM-6268, Placebo - Healthy Volunteers | Phase 1 | Terminated | IGM Biosciences, Inc. | 54 | 2021-12-07 | 2022-10-14 |
| Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars) - Solid Tumor, Colorectal Cancer | Phase 1 | Terminated | IGM Biosciences, Inc. | 272 | 2020-09-23 | 2025-03-28 |
| A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma imvotamab - Non-Hodgkin Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Terminated | IGM Biosciences, Inc. | 97 | 2019-09-30 | 2024-07-24 |
| Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL IGM2323 - Relapsed/Refractory Non-Hodgkin Lymphomas | No longer available | IGM Biosciences, Inc. | 2024-03-26 |
Lymphoma, Non-Hodgkin (2) · Neoplasm Metastasis (2) · Recurrence (2) · Arthritis (1) · Arthritis, Rheumatoid (1) · COVID-19 (1) · Chondrosarcoma (1) · Colorectal Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lupus Erythematosus, Systemic (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1)
IGM-6268 (2) · Azacitidine (1) · Bevacizumab (1) · Docetaxel (1) · Fluorouracil (1) · Gemcitabine (1) · IFL protocol (1) · Irinotecan (1) · Leucovorin (1) · birinapant (1) · venetoclax (1)
United States (8) · South Korea (4) · Australia (3) · Spain (3) · France (2) · Poland (2) · Czechia (1) · Italy (1) · South Africa (1)
Rebecca Kunder (2) · Roel Funke (2) · Eric Humke, MD (1) · Eric Humke, MD, PhD (1) · Thomas Manley, MD (1)